Ad-hoc | 26 April 2001 08:11

Ad hoc-Service: EVOTEC BioSystems AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer has the sole responsibility of this announcement. ——————————————————————————– Evotec OAI and Serono Sign Assay Development and Screening Services Agreement Hamburg, Germany/ Abingdon, UK/ Geneva, Switzerland, April 26, 2001 – Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT) has announced a services agreement with Serono S.A. (SWX: SEO, NYSE; SRA). Under the terms of the agreement, Evotec OAI will develop a novel biological assay for one of Serono’s cellular targets using its proprietary VLiP(TM) technology. After the successful development of this assay, Evotec OAI will perform screening and compound profiling using its EVOscreen technology to identify chemical compounds that mimic one of Serono’s proprietary proteins. Many of the 200,000 compounds to be tested have been synthesised by Evotec OAI for Serono in a separate combinatorial chemistry programme started in 1998. Fees for this new service agreement were not disclosed. The agreement includes an option for Serono to negotiate similar services for additional targets. EVOTEC BioSystems AG Anne Hennecke, Investor Relations Phone: +49-40-56081286 Fax: +49-40-56081333 E-mail: anne.hennecke@evotecoai.com end of ad hoc announcement, (c) DGAP 26.04.2001 ——————————————————————————– WKN: 566480; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 260811 Apr 01